Search
Viatris Inc
VTRSAdd to Watchlist
15.370USD
0.0000.00%
Close 06/22, 16:00（ET）Quotes delayed by 15 min
17.90BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-18The current earnings forecast score of Viatris Inc is 7.33, ranking 103 out of 157 in the Pharmaceuticals industry. The average price target is 13.11, with a high of 15.00 and a low of 9.00.
Analyst Rating
Based on
11
analysts
Buy
Current Rating
17.446
Target Price
+13.50%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
175
Total
6
Median
8
Average
Company name
Ratings
Analysts
Viatris Inc
VTRS
11
Biogen Inc
BIIB
38
Amgen Inc
AMGN
38
Eli Lilly and Co
LLY
35
AbbVie Inc
ABBV
34
Vertex Pharmaceuticals Inc
VRTX
34
1
2
3
...
35
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Viatris Inc's expected revenue for the next quarter?
Viatris Inc's expected revenue is 3.66B.
What is Viatris Inc's price target?
Analysts forecast that Viatris Inc's price target is USD 13.11, with the highest forecast at USD 15.00 and the lowest forecast at USD 9.00.
How have Viatris IncVTRS's recent earnings per share performed?
The market expectation was USD 0.15, while Viatris IncVTRS's earnings per share (EPS) for the previous quarter was USD -3.00. EPS for the next quarter is expected at USD 0.61.
What is the analyst rating for Viatris Inc?
Based on the ratings of Viatris Inc's stock from 11 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
